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Basic research
Translating genetic and preclinical findings
into autism therapies
Maria Chahrour, PhD; Robin J. Kleiman, PhD; M. Chiara Manzini, PhD

Introduction

O

ver the past decade, major advances in genetics and genomics have brought us closer to unraveling
the molecular makeup of autism spectrum disorder
(ASD). ASD is a constellation of neurodevelopmental abnormalities with social deficits and restrictive/repetitive behaviors as its core features. It affects about
1% of the world population and is three to four times
more prevalent in males than in females.1,2 Twin studies
and a more recent large population-based epidemiological study of roughly 2.5 million families have provided clear evidence for a genetic component of ASD
and estimate the disease heritability at around 50% to
95%,3,4 making it one of the most heritable of neuropsychiatric disorders. Furthermore, in all these studies, the
phenotypic concordance between monozygotic twins is
incomplete, indicating that nongenetic environmental
factors play a role in the etiology of ASD. The diversity of contributing risk factors, degree of impairment,
and expressed comorbidities found in individuals with
ASD has created significant roadblocks to the identification of therapeutic targets and successful execution
of clinical trials. In this review, we highlight how human
genetics, induced pluripotent stem-cell (iPSC)-derived
neurons from patients, and murine models can be used

Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder characterized by social deficits and
repetitive/restrictive interests. ASD is associated with multiple comorbidities, including intellectual disability, anxiety, and epilepsy. Evidence that ASD is highly heritable
has spurred major efforts to unravel its genetics, revealing
possible contributions from hundreds of genes through
rare and common variation and through copy-number
changes. In this perspective, we provide an overview of
the current state of ASD genetics and of how genetic research has spurred the development of in vivo and in vitro models using animals and patient cells to evaluate the
impact of genetic mutations on cellular function leading
to disease. Efforts to translate these findings into successful therapies have yet to bear fruit. We discuss how the
valuable insight into the disorder provided by these new
models can be used to better understand ASD and develop future clinical trials.
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Selected abbreviations and acronyms
ASD
CNV
FXS
SHANK3
TSC

autism spectrum disorder
copy number variant
fragile X syndrome
SH3 and multiple ankyrin repeat domains 3
tuberous sclerosis complex

to develop strategies to stratify patients. Cellular models from patient iPSCs can help identify common biochemical pathways altered in patients, and mouse models replicating different human mutations can define
common subsets of affected circuits.

ASD genetics: more patients, more genes
ASD is genetically complex and heterogeneous. To
date, the identified genetic contributions to ASD include large chromosomal abnormalities, submicroscopic deletions or duplications (copy number variants
[CNVs]), and rare single-nucleotide variants (SNVs),
both inherited and de novo (not present in either parent). Common variation is estimated to contribute
40% to 60% of ASD risk with many common variants
each providing a very small effect size.5,6 Genomewide association studies (GWAS) remain underpowered to yield reproducible results because of the genetic heterogeneity of ASD patients.7 There is also an
additive relationship between ASD risk contributed
by rare variants and common polygenic variation.8
Thus, cohorts on the order of tens of thousands of subjects will be needed to identify all common variants,
remaining mindful of the possible contribution from
rare variants.
CNVs associated with ASD are highly heterogeneous, can be inherited9 or arise de novo,10 and are not
specific to the core ASD phenotypes, but are rather associated with a wide range of neuropsychiatric and neurodevelopmental phenotypes.11 The majority of CNVs
have very low recurrence in ASD, and a specific CNV
can often be unique to a single patient. Although the
overall burden of de novo CNVs is higher in affected
than in unaffected individuals, many of the same CNVs
also occur in the unaffected individuals,12 making it
difficult to determine which changes are likely to be
disease-causing. The heterogeneity of CNV-associated
phenotypes can also manifest within a single family as a
result of unidentified modifiers.13

To date, contributions from rare variants in over
700 genes, both de novo and inherited, have been demonstrated in ASD, highlighting its complex genetic architecture. Early studies identified rare ASD-causing
variants in established neurodevelopmental disease
genes, including mutations in FMR1 (Fragile X syndrome; FXS), TSC (Tuberous Sclerosis Complex; TSC),
MECP2 (Rett syndrome), and PTEN among others.
Technological advances that enabled cost-effective sequencing of all protein-coding regions of the genome,
termed whole exome sequencing (WES), allowed for
the identification of coding variants in novel genes associated with “idiopathic,” or nonsyndromic, ASD. WES
studies demonstrated that rare de novo, as well as inherited, SNVs contribute to disease risk—with causative de
novo mutations identified in about 5% of ASD cases14-17
and inherited complete loss of function (LoF) mutations identified in around 5% of ASD cases.18 Network
analyses using high-confidence ASD risk genes with
de novo mutations reveal enrichment for genes encoding chromatin modifiers (eg, CHD8, CHD2, ARID1B),
synaptic signaling molecules (e.g. GRIN2B, GABRB3,
SHANK3), early embryonic development players (eg,
TBR1, DYRK1A, PTEN), and fragile X mental retardation protein (FMRP) targets.19-21 Many of these genes
control transcriptional or signaling cascades that affect
multiple cellular processes.22 Understanding how gene
mutations in different networks converge on disrupted
pathways will define how cases can be stratified for
clinical trials and treatment. For example, if widespread
impairments in Wnt and/or AKT/mTOR signaling signaling23,24 are identified in a range of ASD cases, such
patients could be sorted into related treatment groups.
The overall impact of rare inherited variants on
ASD risk has not been quantified comprehensively,
since current studies do not take into account possible
contributions from missense variants, whose possible
functional impact is difficult to measure. Studies focusing on cohorts of both consanguineous and nonconsanguineous families have shown that rare recessive ASD
mutations display similar heterogeneity in molecular
pathways as shown by de novo mutations. Examples
of ASD genes with recessive LoF mutations identified
in families with ASD, intellectual disability, and other
neurological and behavioral symptoms include CNTNAP2 24, SLC9A9/NHE9 25, BCKDK 26, and CC2D1A.28
Some of the established recessive ASD mutations are
hypomorphic alleles (retaining partial activity) of genes
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whose complete inactivation causes severe neurological syndromes.29 Examples of hypomorphic missense
variants include those in AMT (encoding aminomethyltransferase), PEX7 (encoding peroxisomal biogenesis
factor 7), and VPS13B (encoding vacuolar protein sorting 13 homolog B) that were identified in consanguineous families with ASD. Complete LoF of these genes
leads, respectively, to nonketotic hyperglycinemia, rhizomelic chondrodysplasia punctata, and Cohen syndrome.29 UBE3B is another example of a candidate
ASD gene in which a missense variant was identified30
and was subsequently associated with a syndrome of intellectual disability, lack of speech, and microcephaly.31
Similar to the spectrum and heterogeneity of ASDassociated CNVs, rare SNVs in “nonsyndromic” ASD
genes can be associated with additional neurodevelopmental phenotypes. Thus, mutations in syndromic genes
can also contribute to nonsyndromic ASD.
More recent work has focused on whole genome sequencing (WGS) in ASD cohorts to allow interrogation
of the remaining (approximately) 99% of the genome
that is not covered by WES. These efforts identified de
novo CNVs and SNVs in coding regions of the genome
that were missed by earlier WES studies, as well as variants in new candidate ASD genes.32 In addition, they
suggest a role in ASD risk for de novo variants within
noncoding regulatory regions of the genome.33,34 The
noncoding variants mapped primarily to the untranslated regions (UTRs) of genes and active cis-regulatory
elements.33,34 WGS also suggested a role for paternally
inherited structural variants affecting promoter regions
and UTRs.35
Large-scale sequencing efforts have contributed significantly to our understanding of the complex genetic
architecture of ASD and have begun to define specific
molecular pathways and neuronal circuits disrupted in
ASD patients with common genetic etiologies. The field
is moving toward study of larger cohorts by partnering
with families, clinicians, researchers, and community organizations. One such effort is the Simons Foundation
Powering Autism Research for Knowledge (SPARK),
which aims to build a cohort of 50 000 individuals with
ASD. A second collaboration between Autism Speaks,
Google, and Toronto’s SickKids Hospital has been
named MSSNG, and will perform WGS in 10 000 ASD
families. Future efforts must focus on high-throughput
functional validation to assess the impact of identified
variants on protein function and phenotype develop-

ment, particularly for missense variants. Furthermore,
our understanding of how multiple variants might act in
concert within an individual and the risk from noncoding variation and gene by environment interactions are
still in their infancy.

Preclinical studies in rodents: defining the
circuitry controlling behavior
Modeling dysfunction in rodents has proven useful for
understanding the impact of mutations associated with
neuropsychiatric disorders and for testing possible therapies before use in human studies.36,37 Animal models
of human disorders are expected to meet multiple criteria to be considered valid. They need to recapitulate
the mechanism triggering the disorder, such as a gene
mutation (construct validity), reproduce the symptoms
(biochemical, histological, behavioral) of the disorder
(face validity), and respond to pharmacological interventions as humans would (predictive validity).37,38 Defining to what extent an animal model of ASD is valid
has been difficult.
A primary hurdle in modeling ASD in mice is that
there are no molecular diagnostic measures, eg, a simple
blood test such as blood sugar for diabetes, or a histological readout such as neurofibrillary tangles for Alzheimer disease. The presence of the disorder must be
tested behaviorally in patients. Thus, ethologically appropriate paradigms for rodent or other animal behavior required significant model development to ensure
appropriate translation of results. To this end, multiple
tests for the core features of ASD—sociability and repetitive behaviors—have been developed for use in
conjunction with tests of cognitive deficits and anxiety,
which are frequently comorbid.36 Excellent primers
with the description of recommended behavioral test
batteries for models of ASD and developmental delay
have been published.39,40 Briefly, social function is studied by measuring social preference via interaction and/
or sniffing time in the following situations: (i) between
animals, either stranger or previously encountered,
in the three-chamber test; (ii) between a male and a
stranger receptive female in mating-related interactions; (iii) between young littermates in social play41; or
(iv) with bedding from strangers or cage mates in the
social-conditioned place preference (sCPP) test.42
Repetitive behaviors and restricted interests can be
measured in rodents by measuring instinctual behav-
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iors, such as grooming and digging.43 Changes in selfand reciprocal grooming are a good example of normal
behaviors that can become exaggerated to the point of
shaving (barbering) or injury that is severe enough to
lead to ulcerative lesions. Digging behavior is used as a
proxy for compulsive behavior in obsessive-compulsive
disorder (OCD) models, and the same paradigms are
applied in ASD. One caveat of digging tests is that increased digging is also linked to increased anxiety,44 and
it is difficult to determine intent to confirm that the behavior is in fact excessive and compulsive, as opposed
to recreational or shelter seeking. Finally, animal models of ASD have demonstrated comorbid anxiety and
cognitive deficits that can include impairment in fear
memory, cognitive flexibility, memory acquisition, and
retention across different contexts as measured with
well-established paradigms.45-47
Mouse models with construct validity, ie, engineered
to carry the same genetic mutation found in humans,
have presented constellations of behavioral impairments that partially overlap with the human condition. As the number of mouse lines with ASD gene
mutations is increasing, several comprehensive reviews
have been published to summarize and compare findings,38,39,48 often highlighting the variability in outcomes.
As with patients, there is not a single clear combination of behavioral deficits caused by mutations in ASD
genes. Each mouse line can present with a distinct subset of social and cognitive deficits, and/or anxiety and
repetitive behaviors. However, as different mouse lines
only partially reflect the features of the human disorder, it is difficult to establish face validity. A recent example of this variability comes from four mouse lines
with heterozygous mutations in Chd8, a gene where
frequent LoF de novo mutations have been identified
in ASD.21 Mild social deficits with fewer and longer social encounters were identified in one study,49 normal
interaction with strangers, but no memory of a previously encountered mouse in the three-chamber test, in
another line,50 whereas comprehensive sociability analysis found no deficits in a different mouse.51 Additional
inconsistencies were found in anxiety and cognitive
performance.49-51 The type of genetic mutation, genetic
background, and experimental conditions could be responsible for heterogeneity. Even in disorders like FXS
and TSC with established mouse models for syndromic
ASD,52 translation of preclinical work into clinical trials
has been challenging.

These results imply limited predictive validity for
murine models and have called into question the preclinical use of mice for modeling features of ASD tested
in clinical trials. Moreover, they have revealed significant shortcomings in our knowledge of the molecular
pathways and circuits that regulate behavior in rodents
and humans. We have barely begun to scratch the surface in understanding the circuits involved in the various social paradigms in the mouse, and it remains unclear how tests for repetitive behaviors used to model
obsessive-compulsive behavior will translate to ASD.
Additional behavioral tests may need to be developed
to complement the available ones to reflect other aspects of ASD. Importantly, new assays must demonstrate conservation of underlying molecular processes
and circuits that are responsible for the similar function
in the human brain. Other components of social interaction, such as cooperation, reciprocity, and empathy
may be more relevant to the human disorder, and could
be possible to assay in mice and rats.53
Despite these uncertainties, mouse models have
been useful in dissecting how specific circuits are regulated and altered by mutations in ASD genes. One example is an elegant analysis of the mechanisms involved
in sCPP showing that the preference for bedding linked
to social experiences with cage mates depends on the
reward circuitry in the nucleus accumbens (NAcc) regulated by both oxytocin and serotonin.54 These findings
demonstrate a strong component of reward in remembering the location of a social encounter, and oxytocin
has been shown to modulate NAcc connectivity in social
motivation and perception tasks in children with ASD.55
Mouse studies have also implicated brain regions that
were not traditionally thought to be involved in social
behavior, such as the cerebellum. Heterozygous removal of Tsc1 or Tsc2 in cerebellar Purkinje cells affects
social behavior.52,56 Comparison of multiple ASD models has shown deficits in cerebellar circuits involved in
sensory learning and integration, revealing that sensory
processing in the cerebellum could be a shared deficit
across multiple types of mutations.57
In summary, work in mice has made strong inroads
in understanding how specific genetic mutations alter
cellular function, synaptic transmission, and behavior,
but coordinated and consistent large-scale comparisons of mutations in multiple genes using consistent
experimental conditions is necessary. New behavioral
tests may also be important to unravel the intricacies of
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ASD. As behavioral studies have been often performed
in males, particular attention should be placed in comparing males and females in animal models of ASD.
Baseline behavioral sex-differences must be considered
during interpretation of results, as well as sex-specific
changes in mutant mice, leading to the identification of
possible models of sex bias.58

Patient-derived neurons point to common
cellular and biochemical pathways
Genetics and animal models can provide information
about the developmental risk factors contributing to
ASD, but do not necessarily reveal which therapeutic
targets will improve symptoms after a lifetime of cellular and circuit-driven adaptations to altered neural
function. Patient-derived neurons prepared from iPSCs
can be used to identify drug targets and patient stratification approaches based on common cellular phenotypes and biochemical pathways. Study of iPSC-derived
neurons from syndromic ASD patients has highlighted
impairments of neural development including proliferation, differentiation, and synapse formation.59 These
dysfunctional cellular processes probably contribute to
the changes in neural connectivity described in the context of rodent models and patients. Phenotypes are often associated with disturbances of signal transduction
cascades that include mTOR,60 AKT, extracellular-signal-regulated kinase (ERK),61 and/or Wnt signaling.62
In patient-derived neurons from idiopathic autism,
evidence has been found for disturbances in synaptic
connectivity and function, with changes in expression
of ASD-associated genes, including voltage-gated ion
channels.63
Through use of patient-derived neurons with specific molecular deficits, investigators can identify targeted therapeutic hypotheses. For example, patientderived excitatory neurons from Phelan-McDermid
syndrome (PMDS) are haploinsufficient for SHANK3
and display defects in synaptic transmission and membrane resistance that was corrected by treating neurons
with insulin-like growth factor 1 (IGF1).64 IGF1 treatment was hypothesized to accelerate the maturation of
patient-derived excitatory synapses lacking SHANK3
into more mature synapses that are no longer dependent upon SHANK3 because they contain mature expression of postsynaptic density protein 95 (PSD95)
and N-methyl-d-aspartate (NMDA) receptors.64 This

human developmental sequela was not apparent in murine preparations and may not have been recognized as
a potential therapeutic approach if rodent models had
been studied exclusively. Furthermore, studies of precisely engineered human neurons bearing heterozygous
or homozygous loss of SHANK3 found that the previously observed increases in input resistance in PMDS
neurons may be attributable to an impaired Ih current
that is mediated by hyperpolarization-activated cyclic
nucleotide (HCN)-gated channels.65 The finding that
PMDS phenotypes are mimicked in control neurons
with inhibitors of Ih raises the possibility that Ih channel
potentiators could be a possible druggable target for
neurodevelopmental disorders that exhibit impaired Ih
currents.65 It is worth noting that rodent models of FXS
also exhibit dysregulation of h-channel subunits and
have impaired homeostatic h-channel plasticity.66 Other
disorders that impinge on pathways producing deficits
in maturation of glutamatergic synapse formation might
yield overlapping subsets of patients that could benefit
from similar therapeutic strategies. The development of
techniques that promote rapid transdifferentiation67 of
patient cells into neurons could, theoretically, allow for
prospective stratification of idiopathic ASD patients for
future clinical trials on the basis of properties of their
transdifferentiated neurons.
Modeling neurodevelopmental disorders through
use of human neurons in vitro is creating a valuable substrate for new phenotypic drug screens. The challenges
of working with iPSC-derived models have been documented extensively elsewhere68 and include managing
variability, determining which neuronal cell type and
stage of development to model, and most importantly,
determining what types of cellular end points would
translate to measurable end points in patients. Use of
chemical libraries with annotated mechanisms of action
or US Food and Drug Administration (FDA)-approved
drugs to identify new targets and repurposing opportunities for approved medicines will be especially powerful. Although access to high-quality small-molecule
libraries with well-annotated mechanisms of action can
be challenging for academic investigators, these files
are available from many industry collaborators. Finding mutually acceptable terms for agreements between
academic and industry technology transfer offices is
often a hurdle. Furthermore, limited access to pharmacokinetic data and expertise needed to experimentally
measure drug levels in animal models remains a criti-
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cal roadblock to conducting meaningful translational
follow-up studies in academic settings and requires new
infrastructure.69

Stratification of patients for clinical trials
varies by risk factors and therapeutic target
The heterogeneity of genetic and molecular deficits
found in ASD suggests that a one-size-fits-all therapy
is unlikely. Matching the correct subset of patients to
each potential treatment and finding outcome measures that capture the benefit associated with efficacy
is the biggest challenge to attracting the interest of
commercial drug developers to ASD. Use of genetics
as a stratification approach for clinical trials requires
that the genetic perturbation confer a high degree of
risk to the individual (Figure 1). Monogenic disorders
such as FXS, Rett syndrome, or TSC have been chosen
as the best candidates for subsets of autism on the basis of the assumption that a common genetic defect will
trigger similar compensatory changes. However, even
in monogenic disorders with high penetrance, such as
FXS, there is a broad range of variation in genotype
and phenotype driven by the number of CGG repeats
and epigenetic methylation of the FMR1 promoter.
Clinical trials for FXS have highlighted that there remains significant variability in the response of individual patients to candidate treatments, even when all patients have the same syndrome.70-73 A comprehensive
and thoughtful review of clinical trials conducted in
FXS recently highlighted many of the challenges faced
by investigators to build the infrastructure to recruit,
assess, and enroll patients for the early clinical trials
in FXS.74 The remaining challenge for syndromic ASD
will be to identify measures that accurately capture
benefit for each syndrome and relate them to preclinical data sets.
Preclinical data sets collected with candidate drugs
for FXS often use Fmr1-knockout mice to evaluate
efficacy against phenotypes observed in mice, which
only exhibit a partial overlap with features of the human condition.75 Many preclinical studies focused on
reversal of robust mouse deficits observed in measures
of hippocampal synaptic plasticity (long-term depression [LTD]) and seizure behavior (audiogenic seizures), which provided little insight into what the most
likely benefit would be for a human patient, given that
seizures are not a problem for most FXS patients.76

Early clinical trials for FXS used preexisting outcome
measures, including the Aberrant Behavior Checklist
(ABC) and the Clinical Global Impressions (CGI)
scale. Several subsequent studies conducted in small
patient populations focused on select subscales of
the ABC and expanded the number of clinical scales
evaluated in the hope of finding a subset of sensitive
measures that would support larger, pivotal trials
needed for drug approval.74 Dedicated efforts to develop better clinical tools that are tailored to measure
outcomes for these genetically defined patient populations should improve future success for syndromic
autism.77
Given that most ASD patients do not have a highly
penetrant genetic mutation, nonsyndromic clinical trials will require a biochemical or circuit-driven biomarker to stratify patients into more homogeneous subsets
(Figure 1). For example, emerging evidence shows that
the activity-dependent refinement of cerebellar circuits
is critical to development of appropriate social behavior
in rodent models of ASD; this finding is further supported by human studies that show injury to the cerebellum
early in development is among the highest risk factor
for developing ASD, and developmental malformations are frequently reported in ASD brain (reviewed
by Wang and colleagues78). Visual-motor abnormalities
in saccadic eye movements reported in ASD patients
support the hypothesis that functional integrity of cerebellar circuits is impaired in visually guided tasks in
many individuals with ASD.79 As mentioned above, selective removal of Tsc1 and Tsc2 in cerebellar Purkinje
cells is sufficient to replicate ASD-like deficits in social
approach, social interaction, and water maze reversal
learning.52,56 Furthermore, sensory integration deficits
in the cerebellum are common to mouse models recapitulating inherited and de novo mutations and CNVs
(MECP2, TSC1, SHANK3, CNTNAP2, and 15q11-13
duplication).57
Cerebellar circuitry is highly conserved between
rodents and humans, and it can be monitored functionally in animals and humans of all ages through use
of classical tests of associative eyeblink conditioning.
Associative eyeblink conditioning in normal human
babies exhibits a range of efficiency that can be detected as early as at 1 month of age. The efficiency of
an individual baby’s performance predicts the emergence of social behavior measures at 5 and 9 months
of age.80 Furthermore, conditioned eyeblink response
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has been reported to be impaired in ASD subjects.81,82
Similarly, saccade adaptation abnormalities have been
reported in ASD subjects who adapt slower and demonstrate more variability than healthy controls.79,83 It is
possible that subsets of ASD patients who exhibit cerebellar circuit dysfunction could represent a similarly
impaired subset of idiopathic ASD patients that would
benefit from pharmacological treatments that improve
activity-dependent plasticity in this circuit during early postnatal development, regardless of their genetic
risk factors.
A Strategies for clinical trial stratification
Genes

Pathways

Circuits

•TSC1/2
•FMR1
•MECP2
•CHD8

• AKT/mTOR
dysregulation
• Wnt signaling
• Ion channels

• Cerebellar
dysfunction
• Reward circuitry

Additional ASD patient subsets defined by minimally invasive and highly translatable circuit biomarkers will be needed in order to design clinical trials for
more patients. Consideration for the cost and ease of
screening patients for inclusion criteria, as defined
by new stratification biomarkers, will be a critical element to paving a path to clinical trials, particularly
those conducted over many different sites. For example, electroencephalogram (EEG)-based measures of
hemispheric connectivity applied to naturally sleeping
children84 may have biomarker potential for subsets
of children with similar deficits in connectivity. EEG
technology is commonly available at a broad range of
medical centers and is not cost-prohibitive for large
clinical trials.

Filling the pipeline

B
Rare monogenic disorders
Highly penetrant variants
Polygenic disorders
Weakly penetrant variants
Environmental risk factors

Figure 1. Strategies for clinical trial stratification. The heterogeneity inherent in autism spectrum disorder (ASD) will require
separating patients into more homogeneous subsets to test
specific therapeutic hypotheses. (A) Stratification approaches can be developed on the basis of genetic mutations, biochemical pathways, or neural circuits to yield more homogeneous populations. Stratification based on human genetics
will require that the genes used to narrow the range of the
population confer a very high degree of risk for ASD. This
is the case with monogenic disorders or very highly penetrant variants, such as TSC1/2, FMR1, MECP2, or CHD8 (left
panel). Stratification based on biochemical pathways will be
useful to create subgroups of patients with dysregulation of
specific signaling cascades, such as mTOR, Wnt signaling, or
impaired ion-channel function that are due to dysregulation
from a wide range of de novo or weakly penetrant mutations that impinge on a common pathway (middle panel).
(B) Monogenic/syndromic and nonsyndromic ASD may require different strategies for stratification. Nonsyndromic
ASD is caused by a mixture of genetic and environmental
factors that will be best stratified for clinical trials by monitoring the dysregulation of specific circuits linked to key
symptomatic domains. AKT/mTOR, protein kinase B/mechanistic target of rapamycin; CHD8, chromodomain helicase
DNA-binding protein 8; FMR1, fragile X mental retardation
protein; MECP2, methyl CpG binding protein 2; TSC1/2, tuberous sclerosis complex

Identification of new drug targets to treat ASD is not
enough to attract commercial drug development to
work in this area. A viable path for conducting hypothesis-based clinical trials must be developed for each
patient subset. As additional genes are identified that
confer risk for ASD, preclinical models that evaluate
their impact on human neurons in vitro and genetically
engineered mice in vivo will expand our understanding
of common phenotypes. The advent of CRISPR/Cas9
(clustered regularly interspaced short palindromic
repeats/CRISPR-associated protein-9 nuclease) genome engineering has further opened up the possibility to study animal species with more complex social
behaviors, such as prairie voles or nonhuman primates.
Unraveling the mechanistic basis for circuit-level dysfunction across models and identifying the expression
of translatable biomarkers that reflect homogenous patient subsets will be required to stratify patient populations for future clinical trials. o
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Trasladar los hallazgos genéticos y preclínicos a
las terapias del autismo

Traduire les résultats précliniques et génétiques
en traitement de l’autisme

El trastorno del espectro autista (TEA) es un complejo
trastorno del neurodesarrollo caracterizado por déficits
sociales e intereses repetitivos/restrictivos. El TEA se asocia con múltiples comorbilidades, incluyendo discapacidad intelectual, ansiedad y epilepsia. La evidencia de la
alta heredabilidad del TEA ha estimulado los mayores
esfuerzos para descifrar su genética, revelando posibles
contribuciones de cientos de genes a través de variaciones raras y comunes, y de la variabilidad en el número
de copias. Desde esta perspectiva se entrega una panorámica del estado actual de la genética del TEA y de
cómo la investigación genética ha estimulado el desarrollo de modelos in vivo e in vitro que emplean células
de animales y de pacientes para evaluar el impacto de
las mutaciones genéticas en la función celular que lleva
a la enfermedad. Aún no han dado frutos los esfuerzos
realizados en la traducción de estos hallazgos en terapias exitosas. Se discute cómo se puede emplear la valiosa información acerca del trastorno, proporcionada por
estos nuevos modelos, para una mejor comprensión del
TEA y para desarrollar futuros ensayos clínicos.

Le trouble du spectre de l’autisme (TSA) représente
un trouble complexe neurodéveloppemental caractérisé par des déficits sociaux et des intérêts répétitifs et
restreints. Les comorbidités associées au TSA sont multiples, comme la déficience intellectuelle, l’anxiété et
l’épilepsie. La transmissibilité élevée démontrée du TSA
a encouragé des efforts importants pour décoder sa génétique, des centaines de gènes étant potentiellement
impliqués par des variations rares et courantes et par la
variabilité du nombre de copies. Dans cette perspective,
nous présentons un aperçu de l’état actuel de la génétique du TSA et de la façon dont la recherche génétique
a stimulé le développement de modèles in vivo et in vitro
utilisant des cellules humaines et animales pour évaluer
l’incidence de mutations génétiques sur les fonctions
cellulaires responsables de la maladie. Les efforts pour
traduire ces résultats en traitements efficaces n’ont pas
encore porté leurs fruits. Nous expliquons comment les
informations précieuses apportées par ces nouveaux
modèles peuvent être utilisées pour mieux comprendre
le TSA et développer de futurs essais cliniques.

